{
  "id": "warfarin_management_multipleChoice_v1",
  "type": "multipleChoice",
  "stem": "A patient with atrial fibrillation taking warfarin presents with generalized bruising and an INR of 4.8. Assessment reveals stable vital signs and no active bleeding. Which action should the nurse anticipate?",
  "options": [
    {
      "id": "a",
      "text": "Administer 10 units of Fresh Frozen Plasma (FFP) IV stat."
    },
    {
      "id": "c",
      "text": "Administer Vitamin K 10 mg by slow IV infusion."
    },
    {
      "id": "d",
      "text": "Instruct the patient to increase intake of green leafy vegetables immediately."
    },
    {
      "id": "b",
      "text": "Withhold the next dose of warfarin and monitor for bleeding signs."
    }
  ],
  "correctOptionId": "b",
  "pedagogy": {
    "bloomLevel": "analyze",
    "cjmmStep": "generateSolutions",
    "nclexCategory": "Pharmacological and Parenteral Therapies",
    "difficulty": 3,
    "topicTags": [
      "Warfarin",
      "INR",
      "Anticoagulation",
      "Atrial Fibrillation",
      "Pharmacology"
    ]
  },
  "rationale": {
    "answerBreakdown": [
      {
        "optionId": "a",
        "content": "Incorrect. Fresh Frozen Plasma (FFP) contains all coagulation factors and is used for immediate reversal in life-threatening hemorrhage or before emergency surgery. Risks include Transfusion-Associated Circulatory Overload (TACO) and Transfusion-Related Acute Lung Injury (TRALI). For a stable patient with an INR of 4.8 and no active bleeding, FFP's risks outweigh benefits.",
        "scoring": -1
      },
      {
        "optionId": "c",
        "content": "Incorrect. IV Vitamin K (phytonadione) promotes synthesis of functional clotting factors. It's too aggressive for an INR of 4.8 without significant bleeding, reserved for INRs >10.0 or active bleeding. Rapid reversal can cause a prothrombotic state in atrial fibrillation patients, increasing stroke risk. Anaphylactoid reactions are also a risk.",
        "scoring": -1
      },
      {
        "optionId": "d",
        "content": "Incorrect. Dietary changes are ineffective for acute supratherapeutic INR management. Consistent Vitamin K intake is crucial for long-term warfarin stability, but a sudden increase won't lower the INR quickly or predictably. This destabilizes future dosing by creating a fluctuating Vitamin K baseline.",
        "scoring": -1
      },
      {
        "optionId": "b",
        "content": "Correct. For an INR between 4.5 and 10.0 without active bleeding, guidelines recommend withholding 1-2 warfarin doses. Warfarin's long half-life (36-42 hours) allows plasma concentration to decrease naturally. The liver resumes synthesis of Vitamin K-dependent clotting factors, gradually lowering the INR back to the therapeutic range (2.0-3.0 for A-fib) without over-correction risk.",
        "scoring": 1
      }
    ],
    "pathophysiology": "Warfarin inhibits Vitamin K epoxide reductase complex 1 (VKORC1) in the liver, preventing Vitamin K recycling, essential for activating clotting factors II, VII, IX, and X. An INR of 4.8 indicates significant suppression, creating hemorrhage risk. In a stable patient, withholding warfarin allows natural clotting factor synthesis to resume, safely correcting coagulopathy over 24-48 hours. Active reversal agents can induce a prothrombotic rebound, dangerous in atrial fibrillation.",
    "clinicalPearls": "Monitor for signs of bleeding (e.g., hematuria, melena, epistaxis, gingival bleeding). Educate the patient about consistent Vitamin K intake and the importance of regular INR monitoring. If active bleeding occurs, notify the provider immediately. Ensure the patient understands the signs and symptoms of stroke and the importance of seeking immediate medical attention if they occur.",
    "questionTrap": "The trap is 'intervention bias'—administering FFP or Vitamin K for an abnormal lab and bruising. Differentiate between bruising (coagulopathy evidence) and active bleeding (e.g., GI bleed). For a stable patient with a moderately elevated INR, 'masterful inactivity'—withholding medication and monitoring—is often best.",
    "mnemonics": "HOLD for elevated INR without bleeding:\n- H: High INR (4.5-10.0).\n- O: Observe for bleeding.\n- L: Leave reversal agents alone (no Vitamin K/FFP).\n- D: Discontinue (hold) the next dose(s) and reassess INR.",
    "correct": "Clinical rationale pending deep clinical alignment."
  },
  "scoring": {
    "method": "dichotomous",
    "maxPoints": 1
  },
  "sbar": {
    "situation": "Patient with atrial fibrillation on warfarin presents with generalized bruising and INR of 4.8. Vital signs are stable, no active bleeding.",
    "background": "Patient is on warfarin for atrial fibrillation. Current INR is significantly elevated. No recent changes in medication or diet reported.",
    "assessment": "Patient is stable with generalized bruising, INR 4.8, no active bleeding. Risk for bleeding is increased due to supratherapeutic INR.",
    "recommendation": "Recommend withholding the next dose of warfarin and monitoring INR daily. Assess for any signs of active bleeding. Consider repeating INR in 24 hours to assess trend. Educate patient on signs/symptoms of bleeding and when to seek immediate medical attention. Contact provider if INR continues to rise or if bleeding occurs.",
    "time": "1400"
  },
  "sentinelStatus": "healed_v2026_v8"
}